Bolt Biotherapeutics

88 articles about Bolt Biotherapeutics

• Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

  12/5/2023

  Bolt Biotherapeutics, Inc. today announced that the first patient has been dosed in the Phase 2 clinical trial investigating BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC), as a single agent and in combination with the HER2-targeting antibody pertuzumab.

• Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

  11/9/2023

  Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023, and provided an update on the continued advancement of its clinical programs.

• Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference

  11/7/2023

  Bolt Biotherapeutics announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, Nov. 14, 2023, at 8:35 a.m. EDT in New York, New York.

• Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

  10/23/2023

  Bolt Biotherapeutics (Nasdaq: BOLT) today presented updated data from its Phase 1 dose-escalation trial of BDC-1001 at the European Society for Medical Oncology (ESMO) 2023 Congress, being held in Madrid, Spain and virtually from October 20-24, 2023.

• Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting

  10/18/2023

  Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that it will present four posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

• Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

  10/17/2023

  Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed with BDC-3042 in the single-agent dose-escalation portion of this first-in-human Phase 1/2 clinical study.

• Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

  10/16/2023

  Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) today announced that updated clinical data from its Phase 1/2 dose-escalation study of BDC-1001 will be presented in a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held in Madrid, Spain and virtually from October 20-24, 2023.

• Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

  9/28/2023

  Bolt Biotherapeutics announced that the U.S. Food and Drug Administration granted Orphan Drug Designation for BDC-1001 for the treatment of gastric cancer, including gastroesophageal junction cancer.

• Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

  9/12/2023

  Bolt Biotherapeutics, Inc. announced today the issuance of the first and foundational patent covering BDC-3042. The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 11,753,474 titled “Anti-Dectin-2 Antibodies,” on September 12, 2023.

• Bolt Biotherapeutics to Participate in September Investor Conferences

  9/5/2023

  Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September:

• Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/7/2023

  Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided an update on the continued advancement of its clinical programs.

• Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer

  8/3/2023

  Bolt Biotherapeutics, Inc. today announced that the first patients have been dosed in a Phase 2 dose-expansion clinical trial investigating BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC).

• Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023

  7/31/2023

  Bolt Biotherapeutics (Nasdaq: BOLT) today announced that management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2023 on Monday, August 7, 2023, at 10:00 a.m. EDT (7:00 a.m. PDT).

• Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

  5/25/2023

  Bolt Biotherapeutics, Inc. announced the data from its Phase 1 dose-escalation clinical trial of BDC-1001 that will be presented in a poster session at the American Society of Clinical Oncology 2023 Annual Meeting, being held at McCormick Place in Chicago, Illinois and virtually from June 2-6, 2023.

• Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

  5/11/2023

  Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

• Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

  4/26/2023

  Bolt Biotherapeutics, Inc. announced that it will present a poster with clinical data from its completed Phase 1 dose-escalation study of BDC-1001 at the 2023 American Society for Clinical Oncology Annual Meeting.

• Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  3/29/2023

  Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

• Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies

  3/29/2023

  Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) today reported positive topline data from the company’s recently completed dose-escalation study of BDC-1001 in HER2-expressing solid tumors that support advancing into two Phase 2 studies.

• Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting

  3/14/2023

  Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that it will present a poster with new preclinical data for BDC-3042, a Dectin-2-targeting agonistic antibody, at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2023.

• Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference

  2/28/2023

  Bolt Biotherapeutics announced that management will present a company overview at the Cowen 43rd Annual Healthcare Conference on Tuesday, March 7, 2023, at 2:50 p.m. EST in Boston, Mass.